A new cancer treatment will be made available on the NHS after ‘careful consideration of the evidence’ by the National Institute for Health and Care Excellence (NICE). This decision comes nearly a year since draft guidance said it ‘should not be used routinely’ as there wasn’t enough evidence.

Amivantamab with lazertinib will be made available on the NHS. This will provide a possible treatment for people with a specific form of untreated advanced lung cancer. Hundreds of Brits could benefit from the treatment, according to NICE.

On January 21, it announced the new guidance on X saying: “Just over 1,100 people with a form of advanced lung cancer are set to benefit from a new first-line treatment option today.

• UK-wide 'stay at home' alert over bug causing six symptoms with '48-hour rule'


• Vitamin D users told stop taking if you have one of four symptoms

“Final guidance published by NICE recommends Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer.”

For patients, NICE explained this new development means: “Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish.”

Lazertinib is usually taken as a daily oral tablet while amivantamab is normally administered as an intravenous (IV) infusion. The Medicines and Healthcare products Regulatory Agency originally approved lazertinib with amivantamab as a treatment for these patients last March.

The treatment was already available on the NHS in Scotland but will now be available for patients in England too.

In July 2025, NICE embarked on a consultation to see if the drug should be used in the NHS. Stating in its draft guidance: “Amivantamab plus lazertinib is not required to be funded in the NHS in England… It should not be used routinely in the NHS in England. This is because there is not enough evidence to determine whether amivantamab plus lazertinib is value for money in this population.”

In the consultation, NICE found clinical trial evidence showing the combination of amivantamab plus lazertinib increases how long people have before their condition deteriorates. It could also increase how long people live when compared with other isolated treatment options currently available.

Now it has published the final guidance following this consultation which found: “Amivantamab plus lazertinib must be funded in the NHS in England for the condition and population in the recommendations, if it is considered the most suitable treatment option.

“Amivantamab plus lazertinib must be funded in England within 90 days of final publication of this guidance.

“There is enough evidence to show that amivantamab plus lazertinib provides benefits and value for money, so it can be used routinely across the NHS in this population.”